Colostrum-derived Exosomes for Novel Cancer Therapy 

Cancer remains a major global health burden, causing 9.7 – 10 millions of deaths annually, and current therapies are often limited by poor specificity, systemic toxicity, and inefficient drug delivery. Exosomes, which are small extracellular vesicles involved in intercellular communication, have emerged as promising therapeutic carriers due to their natural ability to transport bioactive molecules. This presentation examines the potential of colostrum-derived exosomes as a novel platform for cancer treatment from literature review.  Colostrum, the first milk produced postpartum, is a rich and safe source of exosomes enriched with immune- and growth-related proteins. Proteomic analyses and experimental studies demonstrate that milk-derived exosomes can reduce tumor growth, increase apoptosis, promote DNA damage in cancer cells, and enhance anti-tumor immune responses in both in vitro and in vivo models. These findings suggest that colostrum-derived exosomes may help overcome key limitations of conventional cancer therapies. However, important challenges could remain, including passing clinical trials tests to get FDA approval, and developing a standardized collection of exosomes for clinical use.